幽门螺杆菌的广泛根除是否会导致耐药性增加
|
摘要
幽门螺杆菌(Helicobacter pylori,Hp)是一种持续性感染,全球人群感染率超过60%。其与许多胃肠道疾病有关,并且可导致恶性肿瘤的发生。幽门螺杆菌感染已成为广泛根除的指征,根除幽门螺杆菌也可有效预防相关胃肠道疾病的发生。由于抗生素的广泛使用和不良反应出现的增多,根除率呈现降低的趋势。近年来,旨在降低幽门螺杆菌耐药的新治疗方法是研究的焦点。文章将对幽门螺杆菌耐药及广泛根除的现状进行阐述,探讨广泛根除和耐药的关系。
Helicobacter pylori(Hp)is a persistent infection that affects more than 60% of the global population.It is associated with many gastrointestinal diseases and even can lead to cancer.H. pylori-infected individuals should be offered eradication therapy, which can also prevent the morbidity of gastrointestinal diseases effectively. Due to the extensive use of antibiotics and the increase of adverse reactions,the eradication rate shows a downward tendency. In recent years, researches have been done focusing on the treatments which can reduce the antibiotic resistance of Helicobacter pylori. This article aims to elaborate the current situation of antibiotic resistance and the eradication of Helicobacter pylori, and discuss the relationship between them.
Helicobacter pylori(Hp)is a persistent infection that affects more than 60% of the global population.It is associated with many gastrointestinal diseases and even can lead to cancer.H. pylori-infected individuals should be offered eradication therapy, which can also prevent the morbidity of gastrointestinal diseases effectively. Due to the extensive use of antibiotics and the increase of adverse reactions,the eradication rate shows a downward tendency. In recent years, researches have been done focusing on the treatments which can reduce the antibiotic resistance of Helicobacter pylori. This article aims to elaborate the current situation of antibiotic resistance and the eradication of Helicobacter pylori, and discuss the relationship between them.
引文
[1]Malfertheiner P,Megraud F,O'Morain CA,et al.Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report[J].Gut,2017,66(1):6-30.
[2]Futami H,Takashima M,Furuta T,et al.Relationship between Helicobacter pylori infection and gastric metaplasia in the duodenal bulb in the pathogenesis of duodenal ulcer[J].J Gastroenterol Hepatol1999,14(2):114-119.
[3]陈旻湖.幽门螺杆菌的传播途径[J].临床消化病杂志,201628(1):66.
[4]Wang J,Ma EM,Wu PF,et al.Multiple intracranial and spinal metastases from a nonfunctioning pituitary adenoma following multiple surgeries:an illustrative case with 16 years of follow-up[J]World J Surg Oncol,2014,12:380.
[5]Burucoa C,Axon A,Axon A.Epidemiology of Helicobacter pylori infection[J].Helicobacter,2017,22 Suppl 1:12514.
[6]张万岱,萧树东.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗,2010,15(5):265-270.
[7]Niv Y,Hazazi R.Helicobacter pylori recurrence in developed and developing countries:meta-analysis of 13C-urea breath test follow-up after eradication[J].Helicobacter,2008,13(1):56-61.
[8]谢勇,陆红,成虹,等.第五次全国幽门螺杆菌感染处理共识报告[J].中国实用内科杂志,2017(06):p.38-53.
[9]NIH Consensus Conference.Helicobacter pylori in peptic ulcer disease.NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease[J].JAMA,1994,272(1):65-69.
[10]Malfertheiner P,Mégraud F,O'Morain C,et al.Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus report.The European Helicobacter Pylori Study Group(EHPSG)[J].Eur J Gastroenterol Hepatol,1997,9(1):1-2.
[11]胡伏莲,胡品津,刘文忠,等.第三次全国幽门螺杆菌感染若干问题共识报告(2007·庐山)[J].现代消化及介入诊疗,200847(1):58-59.
[12]刘文忠,谢勇,成虹,等.第四次全国幽门螺杆菌感染处理共识报告[J].胃肠病学,2012,17.
[13]刘文忠.第五次全国幽门螺杆菌感染处理共识报告解读[J]胃肠病学,2017,22.
[14]秦波.加替沙星等三联疗法治疗幽门螺杆菌感染的疗效观察[J].中国药物与临床,2010,10(12):1382-1383.
[15]De Haan J,Friesen P,Friesen P.Student TXT[J].J Christ Nurs,201936(2):76.
[16]Kim SY,Choi DJ,Chung JW.Antibiotic treatment for Helicobacter pylori:Is the end coming?[J].World J Gastrointest Pharmacol Ther2015.6(4):183-198.
[17]白芳芸.酪酸梭菌联合四联疗法治疗幽门螺杆菌阳性胃溃疡的作用机制研究[J].中国现代医学杂志,2017,277(9):83-86.
[18]De Francesco V,Giorgio F,Hassan C,et al.Worldwide H.pylori antibiotic resistance:a systematic review[J].J Gastrointestin Liver Dis2010,19(4):409-414.
[19]Thung I,Aramin H,Vavinskaya V,et al.Review article:the global emergence of Helicobacter pylori antibiotic resistance[J].Aliment Pharmacol Ther,2016,43(4):514-533.
[20]Zhang YX,Zhou LY,Song ZQ,et al.Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing:a prospective serial study[J].World JGastroenterol,2015,21(9):2786-2792.
[21]Menninger JR,Menninger JR.Functional consequences of binding macrolides to ribosomes[J].J Antimicrob Chemother,1985,16 Suppl A:23-34.
[22]Al-R aw i A,Al-R aw i A.News values on social media:news organizations'Facebook use[J].Journalism(Lond),2017,18(7):871-889.
[23]Umegaki N,Shimoyama T,Nishiya D,et al.Clarithromycin-resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Japan[J].J Gastroenterol Hepatol,2000,15(8):906-909.
[24]Paul TR,Halligan NG,Blaszczak LC,et al.A new mercury-penicillin V derivative as a probe for ultrastructural localization of penicillinbinding proteins in Escherichia coli[J].J Bacteriol,1992,174(14):4689-4700.
[25]Jorgensen MA.The mode of action of metronidazole in Helicobacter pylori:futile cycling or reduction?[J].J Antimicrob Chemother,199841(1):67-75.
[26]Kwon DH,Hulten K,Kato M,et al.DNA sequence analysis of rdxAand frxA from 12 pairs of metronidazole-sensitive and-resistant clinical Helicobacter pylori isolates[J].Antimicrob Agents Chemother,200145(9):2609-2615.
[27]Ribeiro ML,Gerrits MM,Benvengo YH,et al.Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP[J].FEMS Immunol Med Microbiol,2004,40(1):57-61.
[28]Dailidiene D,Bertoli MT,Miciuleviciene J,et al.Emergence of tetracycline resistance in Helicobacter pylori:multiple mutational changes in 16S ribosomal DNA and other genetic loci[J].Antimicrob Agents Chemother,2002,46(12):3940-3946.
[29]Wang B,Lv ZF,Wang YH,et al.Standard triple therapy for Helicobacter pylori infection in China:a meta-analysis[J].World J Gastroenterol2014,20(40):14973-14985.
[30]朱婉萍,孔繁智,陈小囡.牛乳铁蛋白对幽门螺杆菌感染大鼠的治疗实验[J].中国现代应用药学,2008,25(2):85-87.
[31]付强,殷建忠,吴少雄.乳酸菌抗幽门螺旋杆菌感染的研究进展[J].乳业科学与技术,2010,33(2):91-94.
[32]Li P,Chen X,Shen Y,et al.Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm[J].J Control Release,2019,300:52-63.
[33]Saito Y,Konno K,Sato M,et al.Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori[J].Cancers(Basel),2019,11(1):116.
[2]Futami H,Takashima M,Furuta T,et al.Relationship between Helicobacter pylori infection and gastric metaplasia in the duodenal bulb in the pathogenesis of duodenal ulcer[J].J Gastroenterol Hepatol1999,14(2):114-119.
[3]陈旻湖.幽门螺杆菌的传播途径[J].临床消化病杂志,201628(1):66.
[4]Wang J,Ma EM,Wu PF,et al.Multiple intracranial and spinal metastases from a nonfunctioning pituitary adenoma following multiple surgeries:an illustrative case with 16 years of follow-up[J]World J Surg Oncol,2014,12:380.
[5]Burucoa C,Axon A,Axon A.Epidemiology of Helicobacter pylori infection[J].Helicobacter,2017,22 Suppl 1:12514.
[6]张万岱,萧树东.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗,2010,15(5):265-270.
[7]Niv Y,Hazazi R.Helicobacter pylori recurrence in developed and developing countries:meta-analysis of 13C-urea breath test follow-up after eradication[J].Helicobacter,2008,13(1):56-61.
[8]谢勇,陆红,成虹,等.第五次全国幽门螺杆菌感染处理共识报告[J].中国实用内科杂志,2017(06):p.38-53.
[9]NIH Consensus Conference.Helicobacter pylori in peptic ulcer disease.NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease[J].JAMA,1994,272(1):65-69.
[10]Malfertheiner P,Mégraud F,O'Morain C,et al.Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus report.The European Helicobacter Pylori Study Group(EHPSG)[J].Eur J Gastroenterol Hepatol,1997,9(1):1-2.
[11]胡伏莲,胡品津,刘文忠,等.第三次全国幽门螺杆菌感染若干问题共识报告(2007·庐山)[J].现代消化及介入诊疗,200847(1):58-59.
[12]刘文忠,谢勇,成虹,等.第四次全国幽门螺杆菌感染处理共识报告[J].胃肠病学,2012,17.
[13]刘文忠.第五次全国幽门螺杆菌感染处理共识报告解读[J]胃肠病学,2017,22.
[14]秦波.加替沙星等三联疗法治疗幽门螺杆菌感染的疗效观察[J].中国药物与临床,2010,10(12):1382-1383.
[15]De Haan J,Friesen P,Friesen P.Student TXT[J].J Christ Nurs,201936(2):76.
[16]Kim SY,Choi DJ,Chung JW.Antibiotic treatment for Helicobacter pylori:Is the end coming?[J].World J Gastrointest Pharmacol Ther2015.6(4):183-198.
[17]白芳芸.酪酸梭菌联合四联疗法治疗幽门螺杆菌阳性胃溃疡的作用机制研究[J].中国现代医学杂志,2017,277(9):83-86.
[18]De Francesco V,Giorgio F,Hassan C,et al.Worldwide H.pylori antibiotic resistance:a systematic review[J].J Gastrointestin Liver Dis2010,19(4):409-414.
[19]Thung I,Aramin H,Vavinskaya V,et al.Review article:the global emergence of Helicobacter pylori antibiotic resistance[J].Aliment Pharmacol Ther,2016,43(4):514-533.
[20]Zhang YX,Zhou LY,Song ZQ,et al.Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing:a prospective serial study[J].World JGastroenterol,2015,21(9):2786-2792.
[21]Menninger JR,Menninger JR.Functional consequences of binding macrolides to ribosomes[J].J Antimicrob Chemother,1985,16 Suppl A:23-34.
[22]Al-R aw i A,Al-R aw i A.News values on social media:news organizations'Facebook use[J].Journalism(Lond),2017,18(7):871-889.
[23]Umegaki N,Shimoyama T,Nishiya D,et al.Clarithromycin-resistance and point mutations in the 23S rRNA gene in Helicobacter pylori isolates from Japan[J].J Gastroenterol Hepatol,2000,15(8):906-909.
[24]Paul TR,Halligan NG,Blaszczak LC,et al.A new mercury-penicillin V derivative as a probe for ultrastructural localization of penicillinbinding proteins in Escherichia coli[J].J Bacteriol,1992,174(14):4689-4700.
[25]Jorgensen MA.The mode of action of metronidazole in Helicobacter pylori:futile cycling or reduction?[J].J Antimicrob Chemother,199841(1):67-75.
[26]Kwon DH,Hulten K,Kato M,et al.DNA sequence analysis of rdxAand frxA from 12 pairs of metronidazole-sensitive and-resistant clinical Helicobacter pylori isolates[J].Antimicrob Agents Chemother,200145(9):2609-2615.
[27]Ribeiro ML,Gerrits MM,Benvengo YH,et al.Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP[J].FEMS Immunol Med Microbiol,2004,40(1):57-61.
[28]Dailidiene D,Bertoli MT,Miciuleviciene J,et al.Emergence of tetracycline resistance in Helicobacter pylori:multiple mutational changes in 16S ribosomal DNA and other genetic loci[J].Antimicrob Agents Chemother,2002,46(12):3940-3946.
[29]Wang B,Lv ZF,Wang YH,et al.Standard triple therapy for Helicobacter pylori infection in China:a meta-analysis[J].World J Gastroenterol2014,20(40):14973-14985.
[30]朱婉萍,孔繁智,陈小囡.牛乳铁蛋白对幽门螺杆菌感染大鼠的治疗实验[J].中国现代应用药学,2008,25(2):85-87.
[31]付强,殷建忠,吴少雄.乳酸菌抗幽门螺旋杆菌感染的研究进展[J].乳业科学与技术,2010,33(2):91-94.
[32]Li P,Chen X,Shen Y,et al.Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm[J].J Control Release,2019,300:52-63.
[33]Saito Y,Konno K,Sato M,et al.Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori[J].Cancers(Basel),2019,11(1):116.